IN2014DN07410A - - Google Patents
Info
- Publication number
- IN2014DN07410A IN2014DN07410A IN7410DEN2014A IN2014DN07410A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A IN 7410DEN2014 A IN7410DEN2014 A IN 7410DEN2014A IN 2014DN07410 A IN2014DN07410 A IN 2014DN07410A
- Authority
- IN
- India
- Prior art keywords
- pharmaceutically acceptable
- inhibitor
- prodrug
- relates
- pharmaceutical combination
- Prior art date
Links
- 239000013066 combination product Substances 0.000 abstract 1
- 229940127555 combination product Drugs 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261619502P | 2012-04-03 | 2012-04-03 | |
| PCT/US2013/034759 WO2013151913A1 (en) | 2012-04-03 | 2013-04-01 | Tyrosine kinase inhibitor combinations and their use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN07410A true IN2014DN07410A (cg-RX-API-DMAC7.html) | 2015-04-24 |
Family
ID=48184451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN7410DEN2014 IN2014DN07410A (cg-RX-API-DMAC7.html) | 2012-04-03 | 2013-04-01 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20150051210A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2833917A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015512447A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20140146086A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104244982A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013243737B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2866321A1 (cg-RX-API-DMAC7.html) |
| IN (1) | IN2014DN07410A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014011987A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2014143213A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013151913A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2715236C2 (ru) | 2014-03-26 | 2020-02-26 | Астекс Терапьютикс Лтд | Комбинации |
| BR112017001695A2 (pt) * | 2014-07-31 | 2017-11-21 | Novartis Ag | terapia de combinação |
| CA2974937C (en) | 2015-03-25 | 2023-09-05 | National Cancer Center | Therapeutic agent for bile duct cancer |
| CN115177619A (zh) | 2015-12-17 | 2022-10-14 | 卫材R&D管理有限公司 | 用于乳腺癌的治疗剂 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0512324D0 (en) | 2005-06-16 | 2005-07-27 | Novartis Ag | Organic compounds |
| DE102005038537A1 (de) | 2005-08-16 | 2007-02-22 | Merck Patent Gmbh | 1-Acyldihydropyrazolderivate |
| ES2612377T3 (es) | 2005-12-21 | 2017-05-16 | Janssen Pharmaceutica N.V. | Triazolopiridazinas como moduladores de tirosina cinasas |
| NL2000613C2 (nl) | 2006-05-11 | 2007-11-20 | Pfizer Prod Inc | Triazoolpyrazinederivaten. |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| US8507489B2 (en) | 2006-10-23 | 2013-08-13 | Sgx Pharmaceuticals, Inc. | Bicyclic triazoles as protein kinase modulators |
| AU2007323725B2 (en) * | 2006-11-22 | 2014-02-20 | Incyte Holdings Corporation | Imidazotriazines and imidazopyrimidines as kinase inhibitors |
| JP4994044B2 (ja) * | 2007-01-05 | 2012-08-08 | シェブロンジャパン株式会社 | 潤滑油組成物 |
| AU2008239594B2 (en) * | 2007-04-13 | 2013-10-24 | Beth Israel Deaconess Medical Center | Methods for treating cancer resistant to ErbB therapeutics |
| MX2010011959A (es) * | 2008-04-29 | 2010-11-30 | Novartis Ag | Metodos para monitorear la modulacion de la actividad de cinasa del receptor del factor de crecimiento de fibroblastos y uso de dichos metodos. |
| US20110104161A1 (en) * | 2008-05-14 | 2011-05-05 | Burgess Teresa L | Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer |
| JP5781510B2 (ja) * | 2009-08-12 | 2015-09-24 | ノバルティス アーゲー | ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用 |
| JP2013537918A (ja) * | 2010-09-27 | 2013-10-07 | エクセリクシス， インク． | 去勢抵抗性前立腺癌および骨芽細胞骨転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬 |
-
2013
- 2013-04-01 MX MX2014011987A patent/MX2014011987A/es unknown
- 2013-04-01 KR KR1020147027542A patent/KR20140146086A/ko not_active Withdrawn
- 2013-04-01 WO PCT/US2013/034759 patent/WO2013151913A1/en not_active Ceased
- 2013-04-01 AU AU2013243737A patent/AU2013243737B2/en not_active Ceased
- 2013-04-01 US US14/388,251 patent/US20150051210A1/en not_active Abandoned
- 2013-04-01 JP JP2015504647A patent/JP2015512447A/ja active Pending
- 2013-04-01 RU RU2014143213A patent/RU2014143213A/ru not_active Application Discontinuation
- 2013-04-01 EP EP13718671.4A patent/EP2833917A1/en not_active Withdrawn
- 2013-04-01 CA CA2866321A patent/CA2866321A1/en not_active Abandoned
- 2013-04-01 CN CN201380018928.6A patent/CN104244982A/zh active Pending
- 2013-04-01 IN IN7410DEN2014 patent/IN2014DN07410A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2014011987A (es) | 2014-11-10 |
| CN104244982A (zh) | 2014-12-24 |
| KR20140146086A (ko) | 2014-12-24 |
| CA2866321A1 (en) | 2013-10-10 |
| AU2013243737B2 (en) | 2016-06-30 |
| EP2833917A1 (en) | 2015-02-11 |
| US20150051210A1 (en) | 2015-02-19 |
| AU2013243737A1 (en) | 2014-09-25 |
| RU2014143213A (ru) | 2016-05-27 |
| WO2013151913A1 (en) | 2013-10-10 |
| JP2015512447A (ja) | 2015-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2015DN00598A (cg-RX-API-DMAC7.html) | ||
| IN2014DN10670A (cg-RX-API-DMAC7.html) | ||
| MX361499B (es) | Baricitinib deuterado. | |
| PH12014501653A1 (en) | Metalloenzyme inhibitor compounds | |
| MA39749A (fr) | Dérivés de pipéridine-dione | |
| PH12015502091A1 (en) | Cdc7 inhibitors | |
| ZA201409256B (en) | 1,2,4-triazine-6-carboxamide kinase inhibitors | |
| EP3019166A4 (en) | A pharmaceutical combination for the treatment of melanoma | |
| MX366983B (es) | Derivados de 1,5-naftiridina e inhibidores de cinasa de cremallallera de leucina embrionica materna que los contienen. | |
| MX2015008829A (es) | Momelotinib deuterado. | |
| IN2014DN07996A (cg-RX-API-DMAC7.html) | ||
| EP3008651A4 (en) | Cross-store licensing for third party products | |
| IN2014DN11078A (cg-RX-API-DMAC7.html) | ||
| IN2014DN06738A (cg-RX-API-DMAC7.html) | ||
| MX2014015345A (es) | Inhibidores piranopiridona de tanquirasa. | |
| EP3192511A4 (en) | Pharmaceutical containing sodium-dependent phosphate transporter inhibitor | |
| IN2014DN07410A (cg-RX-API-DMAC7.html) | ||
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| NZ717192A (en) | Anti-inflammatory tripeptides | |
| PH12016500809B1 (en) | Glucopyranosyl - substituted indole-urea derivatives and their use as sglt inhibitors | |
| EP3166405A4 (en) | 3'-substituted-abscisic acid derivatives | |
| MX2015012610A (es) | Pacritinib deuterizado. | |
| HK40102341A (zh) | 用於治疗黑素瘤的药物组合 | |
| EP3016535A4 (en) | Modular impact protection system for athletic wear | |
| HK40007630A (en) | Aliphatic prolinamide derivatives |